The debate highlighted major safety concerns about blocking CXCL10, particularly increased infection susceptibility, but no long-term studies exist. This critical safety gap must be resolved before therapeutic development can proceed. Source: Debate session sess_SDA-2026-04-03-gap-aging-mouse-brain-20260402 (Analysis: SDA-2026-04-03-gap-aging-mouse-brain-20260402)
Landscape Summary: Does CXCL10 inhibition compromise CNS immune surveillance during chronic treatment? is a 0.9 priority gap in neuroimmunology. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
Does CXCL10 inhibition compromise CNS immune surveillance during chronic treatment? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: